Hot dots - which nodes should be removed in sentinel lymph node biopsy for melanoma?


Journal

Acta oncologica (Stockholm, Sweden)
ISSN: 1651-226X
Titre abrégé: Acta Oncol
Pays: England
ID NLM: 8709065

Informations de publication

Date de publication:
Sep 2023
Historique:
medline: 23 10 2023
pubmed: 26 7 2023
entrez: 26 7 2023
Statut: ppublish

Résumé

Sentinel lymph node biopsy (SLNB) is a critical staging tool for melanoma patients. The optimal number of lymph nodes removed in SLNB remains unclear. In this study, we retrospectively analysed and tested different criteria for selecting sentinel lymph nodes (SLNs) by radiotracer uptake and blue dye, and their impact on nodal staging. We also evaluated the association between SLN tumour burden and radiotracer uptake. The study population consisted of melanoma patients undergoing SLNB. During the operation all radioactive and blue nodes were removed and sent for histopathological analysis. The Altogether 175 patients with clinically occult metastasis presented with one or more positive, i.e. metastatic, SLNs. The mean number of lymph nodes removed was 4.5, and the mean number of positive lymph nodes was 1.5 per patient. The most radioactive or hottest node was negative in 38 patients (22%). By removing the hottest node and all nodes with radioactivity >10% of the hottest node, 97% of patients would have been staged correctly. In five patients, metastasis was found solely in a SLN with radioactivity <10% of the hottest node. Of all 267 positive nodes removed, 125 (47%) contained blue dye. Patients with a negative hottest node were associated with lower SLN tumour burden. By removing the hottest node and all nodes with radioactivity >10% of the hottest node, 97% of patients with SLN metastases are correctly staged with or without using blue dye.

Sections du résumé

BACKGROUND UNASSIGNED
Sentinel lymph node biopsy (SLNB) is a critical staging tool for melanoma patients. The optimal number of lymph nodes removed in SLNB remains unclear. In this study, we retrospectively analysed and tested different criteria for selecting sentinel lymph nodes (SLNs) by radiotracer uptake and blue dye, and their impact on nodal staging. We also evaluated the association between SLN tumour burden and radiotracer uptake.
METHODS UNASSIGNED
The study population consisted of melanoma patients undergoing SLNB. During the operation all radioactive and blue nodes were removed and sent for histopathological analysis. The
RESULTS UNASSIGNED
Altogether 175 patients with clinically occult metastasis presented with one or more positive, i.e. metastatic, SLNs. The mean number of lymph nodes removed was 4.5, and the mean number of positive lymph nodes was 1.5 per patient. The most radioactive or hottest node was negative in 38 patients (22%). By removing the hottest node and all nodes with radioactivity >10% of the hottest node, 97% of patients would have been staged correctly. In five patients, metastasis was found solely in a SLN with radioactivity <10% of the hottest node. Of all 267 positive nodes removed, 125 (47%) contained blue dye. Patients with a negative hottest node were associated with lower SLN tumour burden.
CONCLUSIONS UNASSIGNED
By removing the hottest node and all nodes with radioactivity >10% of the hottest node, 97% of patients with SLN metastases are correctly staged with or without using blue dye.

Identifiants

pubmed: 37493624
doi: 10.1080/0284186X.2023.2238558
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1021-1027

Auteurs

Mikko Vuoristo (M)

Department of Plastic Surgery, University of Helsinki, and Helsinki University Hospital, Helsinki, Finland.

Susanna Juteau (S)

Department of Pathology, University of Helsinki, and Helsinki University Hospital, Helsinki, Finland.

Virve Koljonen (V)

Department of Plastic Surgery, University of Helsinki, and Helsinki University Hospital, Helsinki, Finland.

Micaela Hernberg (M)

Department of Oncology, University of Helsinki, and Helsinki University Hospital, Helsinki, Finland.

Sorjo Mätzke (S)

Department of Clinical Physiology and Nuclear Medicine, University of Helsinki, and Helsinki University Hospital, Helsinki, Finland.

Suvi Ilmonen (S)

Department of Plastic Surgery, University of Helsinki, and Helsinki University Hospital, Helsinki, Finland.

Tiina Jahkola (T)

Department of Plastic Surgery, University of Helsinki, and Helsinki University Hospital, Helsinki, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH